Get the Stockscreener App
0.4656
4.00%
-0.0194
After Hours:
.48
0.0144
+3.09%
Omega Therapeutics Inc stock is traded at $0.4656, with a volume of 456.07K.
It is down -4.00% in the last 24 hours and down -42.05% over the past month.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
See More
Previous Close:
$0.485
Open:
$0.47
24h Volume:
456.07K
Relative Volume:
1.10
Market Cap:
$25.25M
Revenue:
$3.10M
Net Income/Loss:
$-97.43M
P/E Ratio:
-0.2587
EPS:
-1.8
Net Cash Flow:
$-94.38M
1W Performance:
-2.31%
1M Performance:
-42.05%
6M Performance:
-74.83%
1Y Performance:
-87.31%
1-Day Range:
$0.455
$0.51
1-Week Range:
$0.4431
$0.67
52-Week Range:
$0.4431
$4.4599
Omega Therapeutics Inc Stock (OMGA) Company Profile
Name
Omega Therapeutics Inc
Sector
Industry
Phone
(617) 949-4360
Address
140 FIRST STREET, SUITE 501, CAMBRIDGE
Compare OMGA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMGA
Omega Therapeutics Inc
|
0.4656 | 25.25M | 3.10M | -97.43M | -94.38M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-18-24 | Initiated | Raymond James | Outperform |
| May-25-23 | Resumed | Jefferies | Buy |
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Sep-23-22 | Initiated | Chardan Capital Markets | Buy |
Omega Therapeutics Inc Stock (OMGA) Latest News
Omega Therapeutics announces board reshuffle and new director - MSN
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation - Financial Times
Omega Therapeutics stock hits 52-week low at $0.52 - MSN
Omega Therapeutics stock hits 52-week low at $0.52 By Investing.com - Investing.com Canada
Omega Therapeutics faces loan default notice - Investing.com
Omega Therapeutics faces loan default notice By Investing.com - Investing.com UK
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Omega Therapeutics Announces Director Resignation - Investing.com
Omega Therapeutics Chair Resigns from Board of Directors - Defense World
Omega Therapeutics stock hits 52-week low at $0.74 - Investing.com India
Omega Therapeutics, Inc. Announces Resignation of Michelle C. Werner as Member of the Board of Directors and the Nominating and Corporate Governance Committee - Marketscreener.com
Omega Therapeutics Faces Leadership Change and Takeover Proposal - Yahoo Finance
Omega Therapeutics stock hits 52-week low at $0.74 By Investing.com - Investing.com Canada
Omega Therapeutics Inc (NASDAQ: OMGA) Down -65.47% This Year: What Is Going To Happen Next - Stocks Register
Omega Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Omega Therapeutics announces board changes By Investing.com - Investing.com Nigeria
Omega Therapeutics announces board changes - Investing.com India
Omega Therapeutics Appoints New Director Ravi Mehrotra - TipRanks
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - Citeline News & Insights
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates - MSN
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer – Company Announcement - Financial Times
Piper Sandler Lowers Omega Therapeutics (NASDAQ:OMGA) Price Target to $4.00 - Defense World
Omega Therapeutics Reports Third Quarter 2024 Results - TipRanks
Omega Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Omega Therapeutics stock target cut, keeps Overweight on clinical updates By Investing.com - Investing.com Canada
Shares of Flagship-founded biotech fall as CEO departs - The Business Journals
Omega Therapeutics (NASDAQ:OMGA) Downgraded to Market Perform Rating by Raymond James - MarketBeat
Piper Sandler Issues Pessimistic Forecast for Omega Therapeutics (NASDAQ:OMGA) Stock Price - MarketBeat
Omega Therapeutics Inc (OMGA) Quarterly 10-Q Report - Quartzy
Omega Therapeutics Names Kaan Certel as CEO - MarketWatch
Omega Therapeutics Announces Successful Completion of Phase - GlobeNewswire
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results - The Manila Times
Omega Therapeutics, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner - Financial Times
Omega Therapeutics (NASDAQ:OMGA) Stock Price Down 0.9%Should You Sell? - MarketBeat
Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight - GlobeNewswire
Omega Therapeutics Inc Stock (OMGA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):